Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Merck & Company (MRK)

Merck & Company (MRK)
88.00 x 1,200 88.58 x 300
Post-market by (Cboe BZX)
88.11 +0.24 (+0.27%) 03/26/25 [NYSE]
88.00 x 1,200 88.58 x 300
Post-market 88.15 +0.04 (+0.05%) 19:19 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
87.31
Day High
89.32
Open 88.24
Previous Close 87.87 87.87
Volume 13,810,000 13,810,000
Avg Vol 17,613,789 17,613,789
Stochastic %K 14.68% 14.68%
Weighted Alpha -34.56 -34.56
5-Day Change -5.91 (-6.29%) -5.91 (-6.29%)
52-Week Range 81.04 - 134.63 81.04 - 134.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 221,962,784
  • Shares Outstanding, K 2,526,036
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,221 M
  • EBITDA $ 24,720 M
  • 60-Month Beta 0.35
  • Price/Sales 3.63
  • Price/Cash Flow 9.75
  • Price/Book 5.04

Options Overview Details

View History
  • Implied Volatility 30.02% ( -3.68%)
  • Historical Volatility 25.07%
  • IV Percentile 96%
  • IV Rank 80.23%
  • IV High 33.70% on 03/25/25
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.90
  • Today's Volume 30,456
  • Volume Avg (30-Day) 48,028
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 628,226
  • Open Int (30-Day) 671,650

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.16
  • Number of Estimates 7
  • High Estimate 2.25
  • Low Estimate 2.10
  • Prior Year 2.07
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.08 +1.18%
on 03/25/25
Period Open: 89.38
97.37 -9.51%
on 03/07/25
-1.27 (-1.42%)
since 02/26/25
3-Month
81.04 +8.72%
on 02/18/25
Period Open: 99.87
102.97 -14.43%
on 01/07/25
-11.76 (-11.78%)
since 12/26/24
52-Week
81.04 +8.72%
on 02/18/25
Period Open: 125.52
134.63 -34.55%
on 06/25/24
-37.41 (-29.80%)
since 03/26/24

Most Recent Stories

More News
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also outperformed the sector and the S&P 500 Index in this timeframe. The company's...

MRK : 88.11 (+0.27%)
EXEL : 37.01 (-1.86%)
BMY : 59.21 (+0.03%)
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule Lipoprotein(a)...

AZN : 72.72 (-0.45%)
NVO : 71.73 (-2.54%)
MRK : 88.11 (+0.27%)
Volatility Alert: 10 Stocks Showing High IV Percentile

Volatility can be an option trader's best friend or worst enemy, depending on how it's approached.

LMT : 445.17 (+0.70%)
TSLA : 272.06 (-5.58%)
KKR : 119.44 (-2.24%)
IBM : 250.34 (+0.18%)
MS : 122.20 (-2.40%)
MRK : 88.11 (+0.27%)
MDT : 88.23 (-0.41%)
GS : 573.92 (-2.05%)
UNH : 518.20 (+0.93%)
BMY : 59.21 (+0.03%)
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 88.11 (+0.27%)
REGN : 640.14 (+0.95%)
AMGN : 305.71 (-0.37%)
AXSM : 119.16 (-1.00%)
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed

The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved.

MRK : 88.11 (+0.27%)
VOO : 524.46 (-1.17%)
VTI : 281.16 (-1.17%)
1 Value Stock with Solid Fundamentals and 2 to Turn Down

1 Value Stock with Solid Fundamentals and 2 to Turn Down

MRK : 88.11 (+0.27%)
EPC : 29.74 (+1.40%)
HZO : 23.22 (-0.43%)
2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics...

CRSP : 39.18 (-4.18%)
MRK : 88.11 (+0.27%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 161.72 (+0.43%)
MRK : 88.11 (+0.27%)
LLY : 826.76 (-3.00%)
ABBV : 201.30 (-0.02%)
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market valueThe numerous challenges plaguing the company resulted in the dilution of the stock’s market...

MRK : 88.11 (+0.27%)
SMMT : 19.89 (-1.73%)
MRNA : 31.48 (-7.00%)
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy

/CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab),...

MRK : 88.11 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 91.19
2nd Resistance Point 90.26
1st Resistance Point 89.18
Last Price 88.11
1st Support Level 87.17
2nd Support Level 86.24
3rd Support Level 85.16

See More

52-Week High 134.63
Fibonacci 61.8% 114.16
Fibonacci 50% 107.84
Fibonacci 38.2% 101.51
Last Price 88.11
52-Week Low 81.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.